| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Chronic obstructive pulmonary disease: new therapies and old needs
|
Hopkinson, Nicholas S
|
|
|
13 |
3 |
p. 193-194
|
article
|
| 2 |
Correction to Lancet Respir Med 2025; 13: 244–55
|
|
|
|
13 |
3 |
p. e19
|
article
|
| 3 |
Correction to Lancet Respir Med 2025; 13: 256–71
|
|
|
|
13 |
3 |
p. e19
|
article
|
| 4 |
Corticosteroids in community-acquired pneumonia: a step forward, but questions remain
|
Reyes, Luis Felipe
|
|
|
13 |
3 |
p. 191-193
|
article
|
| 5 |
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
|
Bhatt, Surya P
|
|
|
13 |
3 |
p. 234-243
|
article
|
| 6 |
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
|
Castro, Mario
|
|
|
13 |
3 |
p. 208-220
|
article
|
| 7 |
Home-based monitoring in chronic respiratory diseases: in search of Panacea
|
Roche, Nicolas
|
|
|
13 |
3 |
p. e17-e18
|
article
|
| 8 |
How Glasgow's 1957 tuberculosis screening programme could help countries today
|
Ranscombe, Peter
|
|
|
13 |
3 |
p. 203-204
|
article
|
| 9 |
Idiopathic inflammatory myopathies related lung disease in adults
|
Sehgal, Sameep
|
|
|
13 |
3 |
p. 272-288
|
article
|
| 10 |
Management and mechanisms of eosinophil action in asthma: mind the gap?
|
Russell, Richard E K
|
|
|
13 |
3 |
p. 190-191
|
article
|
| 11 |
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates
|
Duda, Jackie
|
|
|
13 |
3 |
p. 205-206
|
article
|
| 12 |
Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials
|
Smit, Jim M
|
|
|
13 |
3 |
p. 221-233
|
article
|
| 13 |
Social and environmental determinants of health inequities in childhood asthma
|
Alsulami, Saleh
|
|
|
13 |
3 |
p. 197-199
|
article
|
| 14 |
Spirometry—one size doesn't fit all
|
The Lancet Respiratory Medicine,
|
|
|
13 |
3 |
p. 189
|
article
|
| 15 |
Stubble: the Farmer's Bane
|
Burki, Talha
|
|
|
13 |
3 |
p. 207
|
article
|
| 16 |
Vaccine policy experts concerned about second Trump Administration
|
Furlow, Bryant
|
|
|
13 |
3 |
p. 200-201
|
article
|
| 17 |
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
|
Hoppe, Jordana E
|
|
|
13 |
3 |
p. 244-255
|
article
|
| 18 |
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
|
Keating, Claire
|
|
|
13 |
3 |
p. 256-271
|
article
|
| 19 |
What does the expanding CFTR modulator programme mean for people with cystic fibrosis?
|
Southern, Kevin W
|
|
|
13 |
3 |
p. 195-197
|
article
|
| 20 |
Wildfires in southern California: concerns for lung health
|
Burki, Talha
|
|
|
13 |
3 |
p. 202
|
article
|
Journal description